Express News | Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
Arbutus Biopharma Highlights Imdusiran's Potential in Hepatitis B
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting 2024
Arbutus Biopharma CSO Michael Sofia Announces Retirement Plans
JMP Securities Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
Arbutus Biopharma to Share Insights at Viral Hepatitis Conference
Arbutus Biopharma Is Maintained at Buy by Jefferies
Jefferies Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $7
Jefferies analyst Dennis Ding maintains $Arbutus Biopharma(ABUS.US)$ with a buy rating, and adjusts the target price from $5 to $7.According to TipRanks data, the analyst has a success rate of 35.7%
Buy Rating Affirmed for Arbutus Biopharma Amid Positive Legal and Clinical Developments
Arbutus to Participate in Two Upcoming Investor Conferences
Arbutus Biopharma | 10-Q: Q2 2024 Earnings Report
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
Express News | Arbutus Biopharma Corp - if Stipulation Is Granted Would Move Start of the Trial to September 24, 2025
Express News | Arbutus Biopharma Corp - Requesting Amended Case Schedule to Accommodate Certain Outstanding Discovery From Moderna and Third Parties
JMP Securities Maintains Market Outperform on Arbutus Biopharma, Raises Price Target to $5
Arbutus Biopharma Analyst Ratings
H.C. Wainwright Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright analyst Ed Arce maintains $Arbutus Biopharma(ABUS.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 41.8% and
Promising Clinical Advances for Arbutus Biopharma's Imdusiran in Hepatitis B Treatment
Q2 2024 Arbutus Biopharma Corp Earnings Call